Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17563740 | 0.74 | CTSD (0.36) | TAAR1 | |
| SCHEMBL20464071 | 0.73 | TACR1 (0.36) | IDO1TACR1 | |
| SCHEMBL17568875 | 0.72 | NOS1 (0.47) | TAAR1 | |
| SCHEMBL8225452 | 0.71 | LMNA (0.33) | IDO1 | |
| SCHEMBL24140016 | 0.70 | LOXL2 (0.38) | MAOBIDO1TAAR1 | |
| SCHEMBL13491337 | 0.70 | CYP4F2 (0.44) | — | |
| SCHEMBL24852720 | 0.70 | CTSD (0.31) | IDO1 | |
| SCHEMBL17562434 | 0.69 | NOS2 (0.43) | — | |
| SCHEMBL19008154 | 0.69 | MAP4K4 (0.44) | TACR1TAAR1 | |
| SCHEMBL18626558 | 0.68 | MAP4K4 (0.45) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10383861-B2 | 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof | Sammumed, LLC (US) | 2019-08-20 | — | — | US | disclosed |
| US-20180221351-A1 | 3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2018-08-09 | — | — | US | disclosed |
| US-20180221351-A1 | 3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2018-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10383861-B2 | 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof | WNT3, WNT1, WNT3A | MAOB 2520/4885IDO1 1238/4885TACR1 4041/4885 |
| US-20180221351-A1 | 3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF | WNT3, WNT1, WNT3A | MAOB 2520/4885IDO1 1238/4885TACR1 4041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.